The COHCCC strongly supports the design and implementation of investigator-initiated clinical trials that test novel therapeutic agents developed at our institution and innovative applications of currently available agents. Protocol Specific Research Support (PSRS) continues to play an important role in providing preliminary data for extramurally funded proposals. All PSRS-eligible studies are reviewed and approved by the Protocol Review and Monitoring System (PRMS) as described in the PRMS Section. PSRS funding provides the Cancer Center with ongoing support for highly qualified clinical research personnel whose efforts on eligible studies are allocated through the Clinical Trials Office. Funded personnel help manage and ensure the success of protocols by providing a broad range of services in the areas of subject recruitment, data and specimen collection, and protocol compliance. Protocol prioritization and PSRS budget oversight is performed within the clinical research programs themselves and approved by the Center's Deputy Director for Clinical Research. Funding is requested for an appropriate portion of salary support for clinical research nurses, clinical research associates (CRAs), and study coordinators for work supporting PSRS-eligible trials.
The overall goal of Protocol-Specific Research Support is the provision of funding for research nurses and data managers directly involved in the conduct of PSRS-eligible trials. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
|Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828|
|Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118|
|Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141|
|Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :|
|Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5|
|Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165|
|Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171|
|Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520|
|Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328|
|Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394|
Showing the most recent 10 out of 1396 publications